

# Patient Education Materials

## Introduction

The **Hematopoietic Stem Cell Transplantation From Haploidentical Donors in Patients With Hematological Malignancies Using a Treosulfan-Based Preparative Regimen** trial, also known as NCT04195633, is a phase II clinical trial aimed at improving treatment options for patients with blood cancers (hematological malignancies). This trial is crucial in advancing medical knowledge and developing more effective therapies for these conditions.

## Trial Overview

This trial investigates the effectiveness of a donor stem cell transplant, treosulfan, fludarabine, and total-body irradiation in treating patients with blood cancers. The treatment involves chemotherapy and total-body irradiation before the transplant to stop the growth of cancer cells and prevent the patient's immune system from rejecting the donor's stem cells. The donated stem cells may help the patient's bone marrow produce healthy blood cells and immune cells to destroy any remaining cancer cells.

## Purpose and Importance

The purpose of this trial is to evaluate the effectiveness and safety of the treatment regimen in patients with blood cancers. The trial's results could significantly impact the development of new treatments and improve the outcomes for patients with these conditions.

## Participant Experience

Participants will be assigned to one of two treatment arms. Both arms involve receiving treosulfan, fludarabine, and total-body irradiation, followed by an allogeneic hematopoietic stem cell transplantation. After the transplant, participants will receive cyclophosphamide, cyclosporine, mycophenolate sodium or mycophenolate mofetil, and filgrastim. Participants will be followed up at specific intervals after the transplant.

## Potential Benefits and Risks

Potential benefits of participating in this trial include improved treatment outcomes for blood cancers and contributing to medical research. However, there are also potential risks and side effects, such as the possibility of graft-versus-host disease (GVHD), infections, and other complications related to the transplant and chemotherapy.

## Engagement and Support

Participants can expect regular follow-ups and support from the trial team. For any questions or concerns, participants can contact the trial coordinator, Dr. Filippo Milano, at 206.667.5925 or [fmilano@fredhutch.org](mailto:fmilano@fredhutch.org).

## Testimonials or Case Studies

While we cannot share real testimonials due to privacy concerns, consider the following hypothetical scenario:

Sarah, a 35-year-old woman with acute myeloid leukemia, participated in this trial. After receiving the treatment, her cancer went into remission, and she was able to return to her normal life. Sarah expressed gratitude for the opportunity to participate in the trial and contribute to medical research.

## Visual Aids

Please refer to the following visual aids to better understand the trial:

- [Diagram of the treatment process](#)
- [Infographic on the potential benefits and risks](#)

## Frequently Asked Questions (FAQs)

1. **Q:** How long will the trial last? **A:** The trial involves a treatment period, followed by follow-up visits at 28, 56, 84, 365, and 730 days after the transplant.
2. **Q:** What are the eligibility criteria for this trial? **A:** Eligibility criteria include having a specific type of blood cancer, being at least 6 months old, having adequate organ function, and meeting other medical criteria.
3. **Q:** What are the potential side effects of the treatment? **A:** Potential side effects include graft-versus-host disease (GVHD), infections, and other complications related to the transplant and chemotherapy.

## **Call to Action**

If you are interested in participating in this trial or have any questions, please contact the trial coordinator, Dr. Filippo Milano, at 206.667.5925 or [fmilano@fredhutch.org](mailto:fmilano@fredhutch.org). Your participation could make a significant difference in the lives of patients with blood cancers.